Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe


Maxim's Target Price on Biotech Makes It More Than a Tenbagger
Research Report

Share on Stocktwits


Jason Kolbert, an analyst with Maxim Group, provided an update on this biopharmaceutical firm's two recently acquired oncology assets.

Cytori Therapeutics Inc. (CYTX:NASDAQ) recently showed bioequivalence of late-stage ATI-0918, its generic liposomal formulation of doxorubicin, to Johnson & Johnson's Caelyx, which is a branded product in the European Union, Maxim's Jason Kolbert reported in a Nov. 16 research note. Cytori presented the supporting data at the annual meeting of the 2017 American Association of Pharmaceutical Scientists held Nov. 12 to 15.

The bioequivalence for Cytori's ATI-0918 is about 90% of doxorubicin, "which is very good," noted Kolbert. In comparison, generics must fall within 80–125% bioequivalence of the reference product, and the closer to 100%, the better. This confidence interval is characteristic of generics with which regulators are concerned.

About these findings, Kolbert said they "should be very attractive to potential partners." In fact, Maxim Group anticipates that Cytori will pursue a partnership to commercialize ATI-0918.

The biotech is expected to file in H2/18 for approval of this nanomedicine from the European Medicines Agency, and subsequently do the same for ATI-1123, its patented, nanoparticle-stabilized liposomal formulation of docetaxel. "These products both represent significant upside to the Cytori story, neither of which is, in our opinion, being reflected in the current 'distressed' value of the company," wrote Kolbert.

ATI-0918 and ATI-1123 are assets that Cytori gained when it acquired Azaya Therapeutics. "Both represent low-risk, high-reward specialty pharma products that, if monetized, could generate nondilutive capital for the company," Kolbert indicated.

In light of the transaction with Azaya, which closed in Q1/17, Kolbert estimates "a 15% market share and 35% royalty rate for the $300 million European liposomal doxorubicin market with the first year of commercial sales in 2019," he said. To be conservative, Kolbert excludes from his model on Cytori projected revenues from the United States or any other potential market.

Maxim Group has a Buy rating and a $5 per share 12-month target price on Cytori, whose stock is now trading at around $0.38 per share.

Want to read more Life Sciences Report articles like this? Sign up for our free e-newsletter, and you'll learn when new articles have been published. To see recent articles and interviews with industry analysts and commentators, visit our Streetwise Interviews page.

1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following company mentioned in this article is a sponsor of Streetwise Reports: None. Streetwise Reports does not accept stock in exchange for its services. Click here for important disclosures about sponsor fees. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe